Skip to content
Screener

CG Oncology CGON Other Non-Current Assets

Other Non-Current Assets at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$14.27B
Gilead Sciences logo
Gilead SciencesGILD
$295M-20.1%
Aura Biosciences, Inc. logo
Aura Biosciences, Inc.AURA
$517K
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$19.5K-11.3%
UroGen Pharma logo
UroGen PharmaURGN
$8.76M+994%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$6.6M-21.1%

Other financials

Income statement

See full
Revenue$1.2M
Operating income-$86.4M-77.3%
Net income-$79.1M-90.8%
EPS (diluted)-$0.90-66.7%

Balance sheet

See full
Cash & equivalents$19.6M+34.3%
Total debt$8.8M+787%
Total equity$1.0B+53.5%
Total assets$1.1B+54.8%

Cash flow

See full
Operating cash flow-$46.4M-66.0%
CapEx$468.0K+3,243%
Free cash flow-$46.9M-67.6%

Valuation

See full
Market cap$6.66B+265%
Enterprise value$6.65B+267%
P/S1,068.9×-2,245×

Profitability

See full
Operating margin-4,056.2%-1,873pp
Net margin-3,602.7%-1,650pp
FCF margin-2,879.6%-1,307pp

Returns & leverage

See full
Return on equity-26.4%+9.3pp
Debt / equity0.0×
Current ratio22.2×+0.1×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: CG Oncology’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:45 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336918
AssetsJune 30, 2026 / (unaudited)December 31, 2025
Operating lease right-of-use assets5,7303,971
Intangible assets, net545575
Goodwill10,29710,297
Other assets4,7291,678
Total assets$1,085,655$791,592
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$12,727$5,714

Item 1. Financial Statements.

FAQ

What is CG Oncology's other non-current assets?
CG Oncology (CGON) reported other non-current assets of $4.73M in Q2 2026.
How has CG Oncology's other non-current assets changed year-over-year?
CG Oncology's other non-current assets decreased by 82.3% year-over-year, from $26.68M to $4.73M.
What is the long-term trend for CG Oncology's other non-current assets?
Over 2 years (2023 to 2025), CG Oncology's other non-current assets has grown at a 839.8% compound annual growth rate (CAGR), from $19K to $1.68M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about CG Oncology's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude